The UK’s withdrawal from the EU has had an impact on customs procedures, tax and trade, both with the EU and non-EU countries and this also applies to exportation of drug product to the EU from the UK. But what are the implications of this significant manoeuvre for the biopharma and CMO/CDMO sectors? In this guide we review the consequences and impact and the implications for sponsors as they look to get their therapy to market.
Want to be the first to know about our latest capabilities and offerings? Subscribe for Exclusive Updates